Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
NCT04508803
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Treatment Efficacy
Interventions
DRUG:
HX008，Niraparib
DRUG:
HX008，Niraparib
DRUG:
HX008，Niraparib，Trastuzumab
DRUG:
HX008，Niraparib，Pyrrolitinib
Sponsor
Fudan University